Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
BMC Cancer. 2024 Oct 31;24(1):1342. doi: 10.1186/s12885-024-13089-6.
Neuroendocrine tumors (NETs) are rare neoplasms that originate from peptidergic neurons and neuroendocrine cells. Due to their increasing incidence, effective treatment strategies are required. Surufatinib, a novel small-molecule inhibitor with antiangiogenic and immunomodulatory effects, has shown promise in clinical trials for advanced NETs. However, the efficacy and safety of surufatinib are influenced by multiple factors, and there is currently a lack of sufficient real-world studies to explore these potential influencing factors.
We conducted a retrospective study on 133 patients with NETs who were treated with surufatinib at Sun Yat-sen University Cancer Center. Patients were histologically confirmed to have primary NETs. Statistical analyses, including Cox regression models and Kaplan-Meier curves, were conducted to assess the impact of the primary tumor site on progression-free survival (PFS) and overall survival (OS).
Patients with gastroenteropancreatic NETs (GEP-NETs) exhibited significantly longer PFS and OS compared to extraGEP-NETs patients. Subgroup analyses also revealed variations in survival outcomes among patients with liver metastases depending on the primary tumor site. Adverse events (AEs), including proteinuria and increased bilirubin, were more common in GEP-NETs patients. These findings emphasize the importance of considering primary tumor site in treatment decisions for NETs.
Primary tumor site is a critical factor influencing the efficacy of surufatinib in NETs. Clinicians should consider this factor when determining treatment strategies.
神经内分泌肿瘤（NETs）是一种起源于肽能神经元和神经内分泌细胞的罕见肿瘤。由于发病率不断增加，需要有效的治疗策略。Surufatinib 是一种具有抗血管生成和免疫调节作用的新型小分子抑制剂，在晚期 NETs 的临床试验中显示出良好的疗效。然而，Surufatinib 的疗效和安全性受到多种因素的影响，目前缺乏足够的真实世界研究来探讨这些潜在的影响因素。
我们对中山大学肿瘤防治中心接受 Surufatinib 治疗的 133 例 NETs 患者进行了回顾性研究。患者经组织学证实为原发性 NETs。采用 Cox 回归模型和 Kaplan-Meier 曲线进行统计分析，评估原发肿瘤部位对无进展生存期（PFS）和总生存期（OS）的影响。
胃肠胰神经内分泌肿瘤（GEP-NETs）患者的 PFS 和 OS 明显长于非 GEP-NETs 患者。亚组分析还显示，肝转移患者的生存结局因原发肿瘤部位而异。不良事件（AE），包括蛋白尿和胆红素升高，在 GEP-NETs 患者中更为常见。这些发现强调了在 NETs 的治疗决策中考虑原发肿瘤部位的重要性。
原发肿瘤部位是影响 NETs 患者 Surufatinib 疗效的关键因素。临床医生在确定治疗策略时应考虑这一因素。
